OncLive.com· @OncLive · X·· 2 天前评分70
正文 · 原文
Perioperative pembrolizumab plus neoadjuvant chemo did not improve EFS vs placebo plus chemo in pts w/ cisplatin-eligible MIBC undergoing radical cystectomy with pelvic lymph node dissection, according to KEYNOTE-866. @myESMO #ESMO2026 #blcsm #oncology
https://www.onclive.com/view/pembrolizumab-plus-chemo-misses-efs-end-point-in-cisplatin-eligible-mibc
311 浏览 · 3 赞 · 0 转发 · 0 回复
会议摘要
4735O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上
Perioperative pembrolizumab (pembro) or placebo (pbo) + neoadjuvant cisplatin (cis) and gemcitabine (gem) in participants (pts) with muscle-invasive bladder cancer (MIBC): the double-blind, phase 3 KEYNOTE-866 study
https://esmocongress.esmo.org来源：OncLive.com · x.com